Nicola J Gullick

Dr. Nicola J Gullick

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
BMBina Menon
Bina Menon
NGNicola J Gullick
Nicola J Gullick
GWGina J. Walter
Gina J. Walter
MRMegha Rajasekhar
Megha Rajasekhar
TGToby Garrood
Toby Garrood
BKBruce W. Kirkham
Bruce W. Kirkham
Objective: Psoriatic arthritis (PsA) is associated with HLA class I genes, in contrast to the association with HLA class II in rheumatoid arthritis (RA). Since IL‐17+ cells are considered important mediators of synovial inflammation, we sought to determine whether IL‐17–producing CD8+ T cells may be found in the joints of patients with PsA and whether these cells might contribute to the disease process.Methods: Mononuclear cells from paired samples of synovial fluid (SF) and peripheral blood (PB) from patients with PsA or patients with RA were stimulated ex vivo, and CD4− T cells were examined by flow cytometry for cytokine expression, cytotoxic markers, and frequencies of γ/δ or mucosal‐associated invariant T cells. Clinical measures of arthritis activity (C‐reactive protein [CRP] level, erythrocyte sedimentation rate [ESR], Disease Activity Score in 28 joints [DAS28]) and power Doppler ultrasound (PDUS) scores for the presence of active synovitis in the aspirated knee were recorded and assessed for correlations with immunologic markers.Results: Within the CD3+ T cell compartment, both IL‐17+CD4− (predominantly CD8+) and IL‐17+CD4+ T cells were significantly enhanced in the SF compared to the PB of patients with PsA (P = 0.0003 and P = 0.002, respectively; n = 21), whereas in patients with RA, only IL‐17+CD4+ T cells were increased in the SF compared to the PB (P = 0.008; n = 14). The frequency of IL‐17+CD4− T cells in PsA SF was positively correlated with the CRP level (r = 0.52, P = 0.01), ESR (r = 0.59, P = 0.004), and DAS28 (r = 0.52, P = 0.01), and was increased in patients with erosive disease (P < 0.05). In addition, the frequency of IL‐17+CD4− T cells positively correlated with the PDUS score, a marker for active synovitis (r = 0.49, P = 0.04).Conclusion: These results show, for the first time, that the PsA joint, but not the RA joint, is enriched for IL‐17+CD8+ T cells. Moreover, the findings reveal that the levels of this T cell subset are correlated with disease activity measures and the radiographic erosion status after 2 years, suggesting a previously unrecognized contribution of these cells to the pathogenesis of PsA.

14 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
HEHayley G. Evans
Hayley G. Evans
NGNicola J Gullick
Nicola J Gullick
SKStephen Kelly
Stephen Kelly
CPCostantino Pitzalis
Costantino Pitzalis
GLGraham MIchael Lord
Graham MIchael Lord
LTLeonie S. Taams
Leonie S. Taams
Th17 cells are a recently defined subset of proinflammatory T cells that contribute to pathogen clearance and tissue inflammation by means of the production of their signature cytokine IL-17A (henceforth termed IL-17). Although the in vitro requirements for human Th17 development are reasonably well established, it is less clear what their in vivo requirements are. Here, we show that the production of IL-17 by human Th17 cells critically depends on both the activation status and the anatomical location of accessory cells. In vivo activated CD14+ monocytes were derived from the inflamed joints of patients with active rheumatoid arthritis (RA). These cells were found to spontaneously and specifically promote Th17, but not Th1 or Th2 responses, compared with resting CD14+ monocytes from the blood. Surprisingly, unlike Th17 stimulation by monocytes that were in vitro activated with lipopolysaccharide, intracellular IL-17 expression was induced by in vivo activated monocytes in a TNF-α- and IL-1β-independent fashion. No role for IL-6 or IL-23 production by either in vitro or in vivo activated monocytes was found. Instead, in vivo activated monocytes promoted Th17 responses in a cell-contact dependent manner. We propose that, in humans, newly recruited memory CD4 + T cells can be induced to produce IL-17 in nonlymphoid inflamed tissue after cell–cell interactions with activated monocytes. Our data also suggest that different pathways may be utilized for the generation of Th17 responses in situ depending on the site or route of accessory cell activation.

1 January 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
ATAnna Tjärnlund
Anna Tjärnlund
QTQuan Tang
Quan Tang
CWCecilia Wick
Cecilia Wick
MDMaryam Dastmalchi
Maryam Dastmalchi
HMHerman Mann
Herman Mann
ILIngrid E Lundberg
Ingrid E Lundberg
Objectives To study the effects of abatacept on disease activity and on muscle biopsy features of adult patients with dermatomyositis (DM) or polymyositis (PM). Methods Twenty patients with DM (n=9) or PM (n=11) with refractory disease were enrolled in a randomised treatment delayed-start trial to receive either immediate active treatment with intravenous abatacept or a 3 month delayed-start. The primary endpoint was number of responders, defined by the International Myositis Assessment and Clinical Studies Group definition of improvement (DOI), after 6 months of treatment. Secondary endpoints included number of responders in the early treatment arm compared with the delayed treatment arm at 3 months. Repeated muscle biopsies were investigated for cellular markers and cytokines. Results 8/19 patients included in the analyses achieved the DOI at 6 months. At 3 months of study, five (50%) patients were responders after active treatment but only one (11%) patient in the delayed treatment arm. Eight adverse events (AEs) were regarded as related to the drug, four mild and four moderate, and three serious AEs, none related to the drug. There was a significant increase in regulatory T cells (Tregs), whereas other markers were unchanged in repeated muscle biopsies. Conclusions In this pilot study, treatment of patients with DM and PM with abatacept resulted in lower disease activity in nearly half of the patients. In patients with repeat muscle biopsies, an increased frequency of Foxp3+ Tregs suggests a positive effect of treatment in muscle tissue.

27 February 2017 in Rheumatology
Verified
Journal Article
Closed access
JLJo Ledingham
Jo Ledingham
NGNicola J Gullick
Nicola J Gullick
KIKatherine Irving
Katherine Irving
RGRachel Gorodkin
Rachel Gorodkin
MAMelissa Aris
Melissa Aris
JGJames Galloway
James Galloway

4 February 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
HEHayley G. Evans
Hayley G. Evans
URUrmas Roostalu
Urmas Roostalu
GWGina J. Walter
Gina J. Walter
NGNicola J Gullick
Nicola J Gullick
KFKlaus S. Frederiksen
Klaus S. Frederiksen
LTLeonie S. Taams
Leonie S. Taams
IL-17+ CD4+ T (Th17) cells contribute to the pathogenesis of several human inflammatory diseases. Here we demonstrate that TNF inhibitor (TNFi) drugs induce the anti-inflammatory cytokine IL-10 in CD4+ T cells including IL-17+ CD4+ T cells. TNFi-mediated induction of IL-10 in IL-17+ CD4+ T cells is Treg-/Foxp3-independent, requires IL-10 and is overcome by IL-1β. TNFi-exposed IL-17+ CD4+ T cells are molecularly and functionally distinct, with a unique gene signature characterized by expression of IL10 and IKZF3 (encoding Aiolos). We show that Aiolos binds conserved regions in the IL10 locus in IL-17+ CD4+ T cells. Furthermore, IKZF3 and IL10 expression levels correlate in primary CD4+ T cells and Aiolos overexpression is sufficient to drive IL10 in these cells. Our data demonstrate that TNF-α blockade induces IL-10 in CD4+ T cells including Th17 cells and suggest a role for the transcription factor Aiolos in the regulation of IL-10 in CD4+ T cells.

1 August 2011 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
NGNicola J Gullick
Nicola J Gullick
DSDavid L. Scott
David L. Scott